<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increased resistance to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> promotes <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> with aberrant expression of cell survival proteins such as BCL-2 and c-MYC occurring in distinct <z:hpo ids='HP_0002665'>lymphoma</z:hpo> subtypes </plain></SENT>
<SENT sid="1" pm="."><plain>Galectin-3 is an anti-apoptotic protein that protects T cells, macrophages, and <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo> cells from <z:hpo ids='HP_0011420'>death</z:hpo> triggered by a variety of agents </plain></SENT>
<SENT sid="2" pm="."><plain>We have found high levels of galectin-3 protein expression in a subset of B-cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> including diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), primary effusion <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (PEL), and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM), in both cell lines and patient samples </plain></SENT>
<SENT sid="3" pm="."><plain>However, we failed to detect galectin-3 in Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL), marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e>), MALT <z:hpo ids='HP_0002665'>lymphoma</z:hpo> or B-small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (B-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>) cell lines or patient samples </plain></SENT>
<SENT sid="4" pm="."><plain>To determine whether galectin-3 expression protects B cells from <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, galectin-3-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells were transfected with a galectin-3 expressing plasmid, which resulted in markedly increased resistance to anti-Fas-induced cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, galectin-3-positive PEL cells transfected with an amino-terminal truncated galectin-3 vector showed increased sensitivity to anti-Fas induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>During <z:mpath ids='MPATH_458'>normal</z:mpath> B-cell development, galectin-3 expression was lowest in germinal center and plasma B cells, from which <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, PEL, and MM derive, and highest in long-lived na√Øve and memory B cells </plain></SENT>
<SENT sid="7" pm="."><plain>This pattern of expression suggests that aberrantly increased galectin-3 levels in specific B-cell populations may yield a protective advantage during transformation and/or progression of certain B-cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
</text></document>